<DOC>
	<DOCNO>NCT02701673</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose belinostat give combination azacitidine , gemcitabine , busulfan , melphalan patient schedule stem cell transplant . If diffuse large B-cell lymphoma ( DLBCL ) , also receive rituximab . Researchers also want learn safety effectiveness combination .</brief_summary>
	<brief_title>Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation Refractory Relapsed Lymphoma</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign dose level belinostat base join study . Up 5 dose level belinostat test . At least 2 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose belinostat find . All participant receive dose level azacitidine , gemcitabine , busulfan , melphalan . All patient DLBCL also receive dose rituximab . However , first group intolerable side effect , dose level gemcitabine may lower group . Busulfan Test Dose : In stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . You receive test dose busulfan vein 60 minute . This low-level test dose busulfan check level busulfan blood level change time . This information use decide next dose need reach dose level match body size . You likely receive outpatient week admit hospital . If busulfan give outpatient , admitted hospital Day -11 ( 11 day stem cell return body ) test dose give Day -10 . On either Day -11 -10 , blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test 11 time 11 hour test dose busulfan . PK test measure amount study drug body different time point help study doctor determine dose busulfan study . The PK blood draw repeat first day high-dose busulfan treatment ( Day -8 ) . A temporary heparin lock line place vein low number needle stick need draws . If possible PK test perform technical scheduling reason , receive standard fix dose busulfan . About 2 3 day receive test dose busulfan ( depend inpatient outpatient ) , receive palifermin vein 30 second day help decrease risk side effect mouth throat . Study Drug Administration ( patient ) : Beginning Day -8 , swish caphosol glutamine mouth 4 time day 2 minute time . You swish liquid every day leave hospital . You swallow glutamine . These drug use help decrease risk side effect mouth throat . On Day -9 Day -2 , receive belinostat continuously vein . You also receive azacitidine vein day 30 minute . Depending type cancer , also receive rituximab vein 3-6 hour part standard care Day -9 . The study staff tell receive rituximab . On Day -8 , receive gemcitabine vein 4½ hour . On Days -8 , -7 , -6 , -5 , receive busulfan vein 2 hour . On Day -3 , receive gemcitabine vein 4½ hour melphalan vein 30 minute . On Day -2 , receive melphalan vein 30 minute . On Day -1 , rest ( receive chemotherapy ) . On Day 0 , receive stem cell vein 30-60 minute . You receive 3 dos palifermin vein 15-30 second Days 0 , +1 , +2 . As part standard care , receive G-CSF ( filgrastim ) injection skin 1 time day start Day +5 blood cell level return normal . Length Study : As part standard care , remain hospital 3-4 week transplant . After release hospital , continue outpatient Houston area monitor infection transplant-related complication . You take study 100 day transplant . You may take study early disease get bad , intolerable side effect occur , unable follow study direction , choose leave study early . If reason want leave study early , must talk study doctor . It may life-threatening leave study start receive study drug receive stem cell transplant blood cell count dangerously low . Follow-Up : About 100 day transplant : - You physical exam . - Blood ( 4 teaspoon ) urine collect routine test check kidney liver function . - If doctor think need , compute tomography ( CT ) and/or positron emission tomography ( PET ) scan check status disease . - If doctor think need , bone marrow aspiration biopsy check status disease . To collect bone marrow aspiration/biopsy , area hip site numb anesthetic , small amount bone marrow bone withdrawn large needle . This investigational study . Belinostat , busulfan , rituximab FDA approve commercially available treatment lymphoma . Gemcitabine FDA approve commercially available treatment breast cancer , non-small cell lung cancer ( NSCLC ) , ovarian cancer , pancreatic cancer . Melphalan FDA approve commercially available treatment multiple myeloma ( MM ) . Azacitidine FDA approve commercially available treatment myelodysplastic syndrome ( MDS ) . The use study drug combination treat lymphoma consider investigational . Up 60 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<criteria>1 . Age 1565 2 . Patients : 2 . 1 . DLBCL one following : 2.1.1 . Primary refractory ( CR 1st line ) . 2.1.2 . Highrisk relapse ( CR1 &lt; 6 month , secondary IPI &gt; 1 , high LDH ) . 2.1.3 . Refractory relapse : No response ( SD PD ) &gt; /= 1 line salvage . 2.2 . Hodgkin 's one following : 2.2.1 . Primary refractory ( CR 1st line PD within 3 month ) . 2.2.2 . Highrisk relapse ( CR1 &lt; 1 year , extranodal relapse , B symptom ) . 2.2.3 . Refractory relapse : No response ( SD PD ) &gt; /= 1 line salvage . 2.3 . TNHL one following : 2.3.1 . Primary refractory ( &lt; /= CR 1st line relapse within 6 month ) . 2.3.2 . Nonresponsive ( SD/PD ) &gt; /= 1 line salvage . 2.4 . Burkitt 's lymphoblastic lymphoma one following : 2.4.1 . Primary refractory ( &lt; /= CR 1st line relapse within 6 month ) . 2.4.2 . Refractory least 1 line salvage ( SD/PD ) . 3 . Adequate renal function , define estimate serum creatinine clearance &gt; /= 50 ml/min and/or serum creatinine &lt; /= 1.8 mg/dL . 4 . Adequate hepatic function ( SGOT and/or serum glutamate pyruvate transaminase ( SGPT ) &lt; /= 3 x upper limit normal ( ULN ) ; bilirubin ALP &lt; /= 2 x ULN . 5 . Adequate pulmonary function force expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffuse capacity lung carbon monoxide ( DLCO ) ( correct Hgb ) &gt; /= 50 % . 6 . Adequate cardiac function leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 7 . PS &lt; 2 . 8 . Negative Beta human chorionic gonadotropin ( HCG ) woman childbearing potential . 1 . Grade &gt; /= 3 nonhematologic toxicity previous therapy resolve &lt; /= G1 . 2 . Prior whole brain irradiation . 3 . Corrected QT interval ( QTc ) longer 500 ms. 4 . Active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /= 10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 5 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 6 . Active infection require parenteral antibiotic . 7 . HIV infection , unless receive effective antiretroviral therapy undetectable viral load normal cluster differentiation 4 ( CD4 ) count . 8 . Radiation therapy month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Refractory Relapsed Lymphoma</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Caphosol</keyword>
	<keyword>Glutamine</keyword>
	<keyword>Enterex</keyword>
	<keyword>Glutapak-10</keyword>
	<keyword>NutreStore</keyword>
	<keyword>Resource</keyword>
	<keyword>GlutaSolve</keyword>
	<keyword>Sympt-X-G.I .</keyword>
	<keyword>Sympt-X</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Belinostat</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-azacytidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
</DOC>